Editorial introductions.

Abstract

Current Opinion in Oncology was launched in 1989. It is one of a successful series of review journals whose unique format is designed to provide a systematic and critical assessment of the literature as presented in the many primary journals. The field of psychiatry is divided into 15 sections that are reviewed once a year. Each section is assigned a Section Editor, a leading authority in the area, who identifies the most important topics at that time. Here we are pleased to introduce the Journal's Section Editors for this issue. SECTION EDITORS Giuseppe CuriglianoGiuseppe CuriglianoGiuseppe Curigliano, MD, PhD, is Associate Professor of Medical Oncology at the University of Milan, Italy, and the Head of the Division of Early Drug Development at the European Institute of Oncology, Italy. He is a member of the Italian National Health Council since 2018 and, in 2019, he served as Chair of the Scientific Committee of The Lega Nazionale Lotta ai Tumori. He served on the Scientific Committee for the St Gallen Conference since 2011, and was the Scientific Co-Chair in St Gallen in 2017, 2019 and 2021. He served as the Scientific Chair of the IMPAKT ESMO meeting that was held in Brussels in 2014 and as the Breast Cancer Track Chair of the ESMO 2014 meeting. He served as Scientific Co-Chair of the ESMO Breast Cancer Congress in 2019, 2020 and 2021. He is an Editorial Board Member for Annals of Oncology, and serves as Co-Editor in Chief of The Breast, Co-Editor in Chief of Cancer Treatment Reviews, Associate Editor of the European Journal of Cancer, Editor of the Journal of Clinical Oncology. Dr Curigliano serves ESMO as Chair of the Guidelines Committee. He is the Chair of the ESMO Nomination Committee. He was awarded with the first ESO Umberto Veronesi Award in Vienna in 2017 and with the Fellowship of the European Academy of Cancer Sciences in Paris in 2017. He has contributed to over 480 peer-reviewed publications. Marc SansonMarc SansonMarc Sanson, MD, PhD is Professor at Sorbonne Université, Paris, France. He has an activity of clinical neuro-oncology at the Department of Neurology 2, Pitié-Salpêtrière Hospital in Paris. He is also head of the research team “Genetic and Development of Brain Tumors” at the Paris Brain Institute (Institut du Cerveau -ICM). He is the Director of the “CURAMUS” site of Sorbonne-Université which is one of the eight French Sites for Integrated Research on Cancer (SiRIC). Dr Sanson has published many research articles on neuro-oncology, including more than 200 dedicated to gliomas, as well as book chapters, and is a frequently requested lecturer on this topic. His main interest is focused on clinical and translational research on gliomas, including novel targeted therapies, germline and somatic genetic characterisation and development of new biomarkers. He is a reviewer on a number of journals, including the Journal of Clinical Oncology, Nature cancer, Nature Comm, Science Transl Res, Lancet, Lancet Oncology, Annals of Oncology, Annals of Neurology, Neurology, Cancer, Clinical Cancer Research, Cancer Research, Acta Neuropathologica. Dr Sanson earned his MD at University Paris V-Descartes and his PhD at University Paris VII-Diderot. He completed a residency in Neurology in Paris, and a post-doctoral stage at McGill University, Canada. Miguel A. SanzMiguel A. SanzDr Miguel A. Sanz is Researcher Emeritus of the Instituto de Investigación Sanitaria La Fe, Spain, and Honorary Professor of the Department of Medicine at the University of Valencia, Spain. After earning his medical degree at the University of Salamanca in Spain, he was intern, resident and subsequently completed a fellowship in Hematology at the University Hospital La Fe. He was appointed as Head of the Clinical Hematology Section to the University Hospital La Fe in 1977 and then later promoted to Head of the Hematology Department in 2007 as well as Full Professor of Medicine at the University of Valencia. Professor Sanz is Chairman of the Spanish PETHEMA Group and leads the Working Parties of acute promyelocytic leukemia and infections in neutropenic patients. He is currently a reviewer for numerous high-profile medical journals, including all top hematology journals, and has authored more than 580 peer-reviewed papers, numerous book chapters, and in excess of 1100 abstracts at national and international meetings. Prof. Sanz has also lectured widely in Europe, North, central and South America, as well as in the Middle East and Asia, serving as lecturer at the American Society of Hematology and European Hematology Association meetings in several occasions. María-Victoria MateosMaría-Victoria MateosDr María-Victoria Mateos, MD, PhD, is Consultant Physician in the Haematology Department and Associate Professor of Medicine at the University of Salamanca, Spain. She is the director of the Myeloma Program and coordinates the Clinical Trials Unit. She serves as coordinator of GEM (Spanish Myeloma Group), with direct involvement in the design and development of clinical trials. She has coordinated many clinical trials especially in the smouldering myeloma setting and these trials have profoundly influenced current options for the management of these patient populations. She has published over 300 original papers in international journals and her articles had received 29.452 citations (19268 since 2015) with a H index of 79 and 60 since 2015. She is also a member of the IMWG (International MM Working Group), IMS (International MM Society), EHA and ASH. Among her invited presentations, she has contributed to the educational sessions of EHA, ASH and ASCO several times. She has served on the ASH Scientific Committee on plasma cell diseases between 2015 and 2019, and on the EHA's Scientific Program Committee and Advisory Board since 2013 until 2020 being chair of the Scientific Program Committee in 2019. She has been Councillor on the EHA Board since 2015 for a four-year mandate and she remains as member of the Steering Committee for the Society of Hematologic Oncology (SOHO), member of the IMS executive board and member of the European School of Haematology (ESH) Scientific committee. She received the Briand Durie Award in 2019 recognizing excellence in myeloma research.